Reinforces Leadership at Dxcover with Elite Scientific Advisors and Board Members of Global Repute
Dxcover, a pioneering AI-powered multiomic cancer detection company, has announced its foray into the US market to commercialize its innovative technology. In a strategic move, the company has appointed distinguished leaders and expanded its Scientific Advisory Board (SAB) and Board of Directors to bolster its expertise across key areas.
New Leadership Appointments
Marc Jones, an experienced executive with over 25 years in diagnostics, software, and AI-powered platforms, has joined Dxcover as Chief Executive Officer. Jones has a proven track record in driving multiple FDA-cleared and CE-marked products through development, approval, and commercial scale-up. At Altoida, he leads the development of digital biomarkers for neurological diseases using artificial intelligence and real-world data.
Stacy Chick, an accomplished global commercial life sciences executive, has also joined Dxcover. Chick brings extensive experience in transitioning diagnostic innovations from research to commercial stage, developing markets, building commercial operations, and scaling revenues at optimal reimbursement rates. She previously led area sales, operations, analytics, and market access teams at Sanofi. Chick's strategic insights into global market access, reimbursement, and commercial scaling will guide Dxcover through its go-to-market strategy and CLIA rollout.
Expert Additions to Scientific Advisory Board (SAB)
Professor Katy Peters, a leading expert in neuro-oncology and clinical trial design from Duke University Medical Center, has joined the SAB. Her expertise in brain cancer care pathways and translational research is expected to drive advancements in diagnostic innovations, particularly impacting neurology-related oncology diagnostics.
Professor Emma Crosbie from The University of Manchester, an internationally respected clinician-scientist specializing in early detection and prevention of endometrial and ovarian cancers, brings clinical trial and biomarker research expertise. Her role supports Dxcover’s development of early detection strategies in gynecological cancers.
Professor William E. Fisher MD FACS, a pancreatic surgery and oncology expert, has also been appointed to Dxcover's SAB.
Dr. Luke Pike, specializing in CNS malignancies, is another member of Dxcover's SAB.
Professor Katy Peters, Professor Emma Crosbie, Professor William E. Fisher, and Dr. Luke Pike join Professor Paul Brennan, a brain cancer diagnostics expert, on the SAB.
Funding and Future Plans
Dxcover has announced a $6.2M funding round and plans to use these resources to expand its Multiomic Spectral Analysis platform (MOSA-Dx™), facilitating improved diagnostic offerings and expanding access in oncology diagnostics. The company is poised to make significant strides in the field of cancer diagnostics with its AI-powered multiomic test.
These strategic appointments and funding will enable Dxcover to broaden its diagnostic menu into additional cancer types, pursue regulatory milestones, and deliver its technology into the hands of physicians and their patients globally.
[1] Dxcover press release, [link to press release] [2] Dxcover website, [link to website] [3] Altoida press release, [link to press release] [4] Sanofi press release, [link to press release]
- Dxcover, a company focused on digital health and AI-powered multiomic cancer detection, has appointed Marc Jones, an experienced executive in diagnostics, software, and AI-powered platforms, as its new CEO.
- Joining Jones is Stacy Chick, a seasoned commercial life sciences executive with expertise in transitioning diagnostic innovations to commercial stage, who will guide Dxcover's go-to-market strategy and CLIA rollout.
- The company has also expanded its Scientific Advisory Board (SAB) with notable additions, including Professor Katy Peters, a leading expert in neuro-oncology and clinical trial design, and Professor Emma Crosbie, a clinician-scientist focusing on early detection and prevention of endometrial and ovarian cancers.
- With its strategic appointments and a $6.2M funding round, Dxcover aims to broaden its diagnostic menu, pursue regulatory milestones, and deliver its AI-powered multiomic test into the hands of physicians, impacting various medical-conditions such as cancer.
- Health tech investors and stakeholders can follow Dxcover's progress by visiting its website or referring to relevant press releases from Dxcover, Altoida, Sanofi, and other related sources.
- In the realm of health and wellness, finance, and investing, Dxcover emerged as a promising company in the business of health tech, leveraging technology and science to eventually revolutionize the diagnosis and treatment of numerous medical-conditions such as cancer, utilizing artificial intelligence and real-world data.
